HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Le, H. N. Articles by Norton, J. A. Search for Related Content PubMed PubMed Citation Articles by Le, H. N. Articles by Norton, J. A.

Pre-Existing Tumor-Sensitized T Cells Are Essential for Eradication of Established Tumors by IL-12 and Cyclophosphamide Plus IL-12¹

Department of Surgery, University of California and San Francisco Veterans Affairs Medical Center, San Francisco, CA 94121

The antitumor immune response activated by IL-12, especially by a combination of cyclophosphamide and IL-12 (Cy+IL-12), is clinically significant in certain experimental tumor models, in that a number of well-established (10–20 mm in diameter) s.c. tumors are completely eradicated. Furthermore, Cy+IL-12 treatment is also able to eradicate well-established grossly detectable experimental lung metastases and advanced ascites tumors. Despite the dramatic antitumor effects seen in some tumor models, Cy+IL-12 fails to induce regression of other established tumors. Characterization of tumor immunogenicity shows that all tumors responding to IL-12 and Cy+IL-12 treatments are immunogenic tumors, in that an antitumor immune response is detectable in tumor-bearing hosts upon tumor establishment. In contrast, none of the nonimmunogenic tumor responds to IL-12 and Cy+IL-12 treatments. Analysis of cellular requirements for successful tumor rejection through an adoptive cell transfer approach reveals that the presence of tumor-sensitized, but not naive, T cells is essential for tumor rejection by IL-12 and Cy+IL-12. Transfer of these tumor-sensitized T cells must be conducted before, but not after, IL-12 treatment in order for tumor rejection to occur. The requirement of sensitized T cells is also tumor specific. In mice bearing immunogenic tumors, the presence of pre-existing tumor-sensitized T cells is demonstrated by adoptive cell transfer experiments using purified spleen T cells from these mice. Results from our study show that Cy+IL-12-based immunotherapy of cancer may be highly effective and that pre-existing tumor-sensitized T cells are essential for the success of the therapy.

This article has been cited by other articles:

				M. Robinson, B. Li, Y. Ge, D. Ko, S. Yendluri, T. Harding, M. VanRoey, K. R. Spindler, and K. Jooss Novel Immunocompetent Murine Tumor Model for Evaluation of Conditionally Replication-Competent (Oncolytic) Murine Adenoviral Vectors J. Virol., April 15, 2009; 83(8): 3450 - 3462. [Abstract] [Full Text] [PDF]

				A. N. Rad, G. Pollara, S. M. A. Sohaib, C. Chiang, B. M. Chain, and D. R. Katz The Differential Influence of Allogeneic Tumor Cell Death via DNA Damage on Dendritic Cell Maturation and Antigen Presentation Cancer Res., August 15, 2003; 63(16): 5143 - 5150. [Abstract] [Full Text] [PDF]

				A. H. Mandpe, K. Tsung, and J. A. Norton Cure of an Established Nonimmunogenic Tumor, SCC VII, With a Novel Interleukin 12-Based Immunotherapy Regimen in C3H Mice Arch Otolaryngol Head Neck Surg, July 1, 2003; 129(7): 786 - 792. [Abstract] [Full Text] [PDF]

				S. D. Hess, N. K. Egilmez, N. Bailey, T. M. Anderson, E. Mathiowitz, S. H. Bernstein, and R. B. Bankert Human CD4+ T Cells Present Within the Microenvironment of Human Lung Tumors Are Mobilized by the Local and Sustained Release of IL-12 to Kill Tumors In Situ by Indirect Effects of IFN-{gamma} J. Immunol., January 1, 2003; 170(1): 400 - 412. [Abstract] [Full Text] [PDF]

				H. C. Hill, T. F. Conway Jr., M. S. Sabel, Y. S. Jong, E. Mathiowitz, R. B. Bankert, and N. K. Egilmez Cancer Immunotherapy with Interleukin 12 and Granulocyte-Macrophage Colony-stimulating Factor-encapsulated Microspheres: Coinduction of Innate and Adaptive Antitumor Immunity and Cure of Disseminated Disease Cancer Res., December 15, 2002; 62(24): 7254 - 7263. [Abstract] [Full Text] [PDF]

				K. Tsung, J. P. Dolan, Y. L. Tsung, and J. A. Norton Macrophages as Effector Cells in Interleukin 12-induced T Cell-dependent Tumor Rejection Cancer Res., September 1, 2002; 62(17): 5069 - 5075. [Abstract] [Full Text] [PDF]

				J. G. Segal, N. C. Lee, Y. L. Tsung, J. A. Norton, and K. Tsung The Role of IFN-{gamma} in Rejection of Established Tumors by IL-12 : Source of Production and Target Cancer Res., August 15, 2002; 62(16): 4696 - 4703. [Abstract] [Full Text] [PDF]